Regeneron UK

Latest clinical program signals indexed for Regeneron UK.

1. VGFT-OD-0508 — Phase 2

   Jun 8, 2026
   Clinical update →

2. R727-CL-1112 — Phase 3

   Jun 8, 2026
   Clinical update →

3. 17508 — Approved

   Jun 8, 2026
   Clinical update →

4. ARD6123 — Phase 2

   Jun 8, 2026
   Clinical update →

5. EFC10547 — Phase 3

   Jun 8, 2026
   Clinical update →

6. EFC6125 — Phase 3

   Jun 8, 2026
   Clinical update →

7. ARD6122 — Phase 2

   Jun 8, 2026
   Clinical update →

8. EFC10261 — Phase 3

   Jun 8, 2026
   Clinical update →

1. NCT00036946

   ziv-aflibercept

   Phase 1 · completed · mab

   Lymphoma

   CT.gov ↗
2. NCT00045266

   ziv-aflibercept

   Phase 1 · completed · mab

   Lymphoma

   CT.gov ↗
3. NCT00082823

   ziv-aflibercept

   Phase 1 · completed · mab

   Cancer

   CT.gov ↗
4. NCT00083213

   ziv-aflibercept

   Phase 1 · completed · mab

   Cancer

   CT.gov ↗
5. NCT00284141

   ARD6123

   Phase 2 · completed · small_molecule

   Pulmonary Diseases

   CT.gov ↗
6. NCT00288704

   rilonacept 160 mg

   Phase 3 · completed · small_molecule

   Familial Cold Autoinflammatory Syndrome (FCAS)

   CT.gov ↗
7. NCT00320775

   VEGF Trap

   Phase 1 · completed · small_molecule

   Macular Degeneration

   CT.gov ↗
8. NCT00320788

   VGFT-OD-0508

   Phase 2 · completed · mab

   Macular Degeneration

   CT.gov ↗
9. NCT00320814

   VEGF Trap-Eye

   Phase 1 · completed · small_molecule

   Diabetic Macular Edema

   CT.gov ↗
10. NCT00327171

    ARD6122

    Phase 2 · completed · small_molecule

    Neoplasms

    CT.gov ↗
11. NCT00327444

    EFC6125

    Phase 3 · completed · small_molecule

    Ovarian Neoplasms

    CT.gov ↗
12. NCT00383370

    VEGF Trap

    Phase 1 · completed · small_molecule

    Neovascular Age Related Macular Degeneration

    CT.gov ↗
13. NCT00396591

    EFC6125

    Phase 3 · completed · small_molecule

    Ovarian Neoplasms

    CT.gov ↗
14. NCT00479076

    aflibercept (AVE0005)

    Phase 1 · completed · small_molecule

    Neoplasms

    CT.gov ↗
15. NCT00509795

    Ranibizumab

    Phase 3 · completed · small_molecule

    Macular Degeneration

    CT.gov ↗
16. NCT00519285

    Aflibercept

    Phase 3 · completed · small_molecule

    Prostatic Neoplasms

    CT.gov ↗
17. NCT00527423

    VEGF Trap Eye

    Phase 2 · completed · small_molecule

    Macular Degeneration

    CT.gov ↗
18. NCT00532155

    EFC10261

    Phase 3 · completed · small_molecule

    Carcinoma

    CT.gov ↗
19. NCT00545246

    aflibercept (AVE0005)

    Phase 1 · completed · small_molecule

    Neoplasms

    CT.gov ↗
20. NCT00561470

    Placebo

    Phase 3 · completed · small_molecule

    Colorectal Neoplasms

    CT.gov ↗
21. NCT00574275

    EFC10547

    Phase 3 · terminated · small_molecule

    Pancreatic Neoplasm

    CT.gov ↗
22. NCT00609544

    Rilonacept

    Phase 2 · terminated · small_molecule

    Chronic Kidney Disease

    CT.gov ↗
23. NCT00610363

    Rilonacept

    Phase 3 · completed · mab

    Gout

    CT.gov ↗
24. NCT00637377

    Ranibizumab

    Phase 3 · completed · small_molecule

    Macular Degeneration

    CT.gov ↗
25. NCT00644124

    aflibercept

    Phase 1 · completed · small_molecule

    Lymphoma, Non-Hodgkin

    CT.gov ↗
26. NCT00789477

    Intravitreal Aflibercept Injection

    Phase 2 · completed · small_molecule

    Diabetic Macular Edema

    CT.gov ↗
27. NCT00794417

    Aflibercept

    Phase 2 · terminated · small_molecule

    Advanced Carcinoma

    CT.gov ↗
28. NCT00829829

    Rilonacept 80 mg

    Phase 3 · completed · small_molecule

    Intercritical Gout

    CT.gov ↗
29. NCT00855920

    Rilonacept

    Phase 3 · completed · small_molecule

    Acute Gout Flare

    CT.gov ↗
30. NCT00856206

    Rilonacept

    Phase 3 · completed · mab

    Gout

    CT.gov ↗
31. NCT00856310

    REGN475 (SAR164877)

    Phase 1 · completed · mab

    Healthy

    CT.gov ↗
32. NCT00871559

    REGN421(SAR153192)

    Phase 1 · completed · small_molecule

    Advanced Solid Malignancies

    CT.gov ↗
33. NCT00876044

    aflibercept (AVE0005)

    Phase 1 · completed · small_molecule

    Cancer

    CT.gov ↗
34. NCT00921661

    AVE0005 (aflibercept)

    Phase 1 · completed · small_molecule

    Colorectal Neoplasms

    CT.gov ↗
35. NCT00943072

    VEGF Trap-Eye 2.0mg

    Phase 3 · completed · mab

    Macular Edema Secondary to Central Retinal Vein Occlusion

    CT.gov ↗
36. NCT00944892

    REGN475

    Phase 2 · completed · small_molecule

    Osteoarthritis of the Knee

    CT.gov ↗
37. NCT00958438

    Placebo

    Phase 3 · completed · small_molecule

    Gout

    CT.gov ↗
38. NCT00964795

    Intravitreal Aflibercept Injection 2mg

    Approved · active · small_molecule

    Neovascular Age-related Macular Degeneration

    CT.gov ↗
39. NCT00991172

    REGN475

    Phase 2 · completed · small_molecule

    Sciatica

    CT.gov ↗
40. NCT01001715

    REGN475/SAR164877

    Phase 2 · terminated · small_molecule

    Back Pain

    CT.gov ↗
41. NCT01001923

    REGN475/SAR164877

    Phase 2 · terminated · small_molecule

    Abdominal Pain Upper

    CT.gov ↗
42. NCT01011959

    REGN88

    Phase 1 · completed · mab

    Rheumatoid Arthritis

    CT.gov ↗
43. NCT01012973

    14130

    Phase 3 · completed · mab

    Retinal Vein Occlusion

    CT.gov ↗
44. NCT01015027

    REGN668

    Phase 1 · completed · mab

    Healthy

    CT.gov ↗
45. NCT01026519

    REGN88

    Phase 1 · completed · mab

    Rheumatoid Arthritis

    CT.gov ↗
46. NCT01026597

    REGN727

    Phase 1 · completed · small_molecule

    Healthy

    CT.gov ↗
47. NCT01053702

    R475

    Phase 2 · terminated · small_molecule

    Thermal Injury Pain

    CT.gov ↗
48. NCT01055899

    REGN88

    Phase 1 · completed · mab

    Rheumatoid Arthritis

    CT.gov ↗
49. NCT01061723

    Sarilumab

    Phase 2 · terminated · small_molecule

    Ankylosing Spondylitis

    CT.gov ↗
50. NCT01061736

    Sarilumab

    Approved · terminated · small_molecule

    Rheumatoid Arthritis

    CT.gov ↗
51. NCT01074372

    REGN727

    Phase 1 · completed · small_molecule

    Healthy Volunteers

    CT.gov ↗
52. NCT01118728

    Sarilumab

    Phase 2 · terminated · small_molecule

    Ankylosing Spondylitis

    CT.gov ↗
53. NCT01146652

    SAR153191 (REGN88)

    Phase 3 · completed · small_molecule

    Rheumatoid Arthritis

    CT.gov ↗
54. NCT01148615

    Aflibercept (AVE0005)

    Phase 1 · completed · small_molecule

    Neoplasm Malignant

    CT.gov ↗
55. NCT01161082

    REGN727(SAR236553)

    Phase 1 · completed · small_molecule

    Hypercholesterolemia

    CT.gov ↗
56. NCT01197391

    REGN728

    Phase 1 · completed · mab

    Healthy

    CT.gov ↗
57. NCT01209793

    REGN846

    Phase 1 · completed · mab

    Healthy

    CT.gov ↗
58. NCT01217814

    Sarilumab

    Approved · terminated · small_molecule

    Rheumatoid Arthritis

    CT.gov ↗
59. NCT01239017

    REGN475

    Phase 2 · terminated · mab

    Osteoarthritis

    CT.gov ↗
60. NCT01249664

    VEGF Trap-Eye (BAY86-5321)

    Phase 3 · completed · mab

    Myopia, Pathological

    CT.gov ↗
61. NCT01259323

    REGN668

    Phase 1 · completed · mab

    Dermatitis

    CT.gov ↗
62. NCT01266876

    Alirocumab

    Phase 3 · active · small_molecule

    Hypercholesterolemia

    CT.gov ↗
63. NCT01271972

    nesvacumab (REGN910/ SAR307746)

    Phase 1 · completed · small_molecule

    Solid Tumors

    CT.gov ↗
64. NCT01288443

    Alirocumab

    Phase 3 · active · small_molecule

    Hypercholesterolemia

    CT.gov ↗
65. NCT01288469

    Alirocumab

    Phase 3 · active · small_molecule

    Hypercholesterolemia

    CT.gov ↗
66. NCT01312961

    Dupilumab

    Approved · active · small_molecule

    Asthma

    CT.gov ↗
67. NCT01328522

    SAR153191 (REGN88)

    Phase 3 · completed · small_molecule

    Rheumatoid Arthritis

    CT.gov ↗
68. NCT01331681

    VEGF Trap-Eye (BAY86-5321)

    Phase 3 · completed · mab

    Diabetes Mellitus

    CT.gov ↗
69. NCT01363440

    Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)

    Phase 3 · completed · small_molecule

    Diabetic Macular Edema

    CT.gov ↗
70. NCT01385657

    Placebo

    Phase 1 · completed · small_molecule

    Atopic Dermatitis

    CT.gov ↗
71. NCT01443650

    alirocumab SAR236553 (REGN727)

    Phase 3 · completed · small_molecule

    Hypercholesterolemia

    CT.gov ↗
72. NCT01448239

    alirocumab SAR236553 (REGN727)

    Phase 3 · completed · small_molecule

    Hypercholesterolemia

    CT.gov ↗
73. NCT01448304

    alirocumab SAR236553 (REGN727)

    Phase 3 · completed · small_molecule

    Hypercholesterolemia

    CT.gov ↗
74. NCT01448317

    Alirocumab (Solution)

    Phase 1 · completed · small_molecule

    Hypercholesterolemia

    CT.gov ↗
75. NCT01451645

    Colchicine (Colcrys®)

    Approved · completed · small_molecule

    Intercritical Gout

    CT.gov ↗
76. NCT01459796

    Rilonacept

    Phase 3 · completed · mab

    Gout

    CT.gov ↗
77. NCT01482910

    13406

    Phase 3 · completed · mab

    Macular Degeneration

    CT.gov ↗
78. NCT01484600

    REGN668: Injection Rate 1

    Phase 1 · completed · small_molecule

    Healthy

    CT.gov ↗
79. NCT01495208

    Aflibercept

    Approved · terminated · small_molecule

    Fibrovascular Pigment Epithelial Detachment

    CT.gov ↗
80. NCT01507402

    REGN1033 (SAR391786)

    Phase 1 · completed · small_molecule

    Healthy Volunteers

    CT.gov ↗
81. NCT01507831

    Placebo (for alirocumab)

    Phase 3 · completed · small_molecule

    Hypercholesterolemia

    CT.gov ↗
82. NCT01512966

    VEGF Trap-Eye (BAY86-5321)

    Phase 3 · completed · mab

    Macular Edema

    CT.gov ↗
83. NCT01521559

    Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)

    Phase 3 · completed · small_molecule

    Branch Retinal Vein Occlusion

    CT.gov ↗
84. NCT01537640

    SAR231893 (REGN668) DP1

    Phase 1 · completed · mab

    Healthy

    CT.gov ↗
85. NCT01537653

    SAR231893 (REGN668)

    Phase 1 · completed · small_molecule

    Healthy

    CT.gov ↗
86. NCT01538719

    Rilonacept

    Phase 2 · completed · small_molecule

    Scleroderma

    CT.gov ↗
87. NCT01540539

    REGN1154 or placebo

    Phase 1 · completed · small_molecule

    Healthy Volunteers

    CT.gov ↗
88. NCT01543568

    aflibercept 2.0 mg

    Approved · completed · small_molecule

    Age Related Macular Degeneration

    CT.gov ↗
89. NCT01548404

    Placebo

    Phase 1 · completed · small_molecule

    Atopic Dermatitis

    CT.gov ↗
90. NCT01571284

    Aflibercept AVE0005

    Phase 3 · terminated · small_molecule

    Colorectal Cancer Metastatic

    CT.gov ↗
91. NCT01576484

    Alirocumab

    Phase 3 · active · small_molecule

    Hypercholesterolemia

    CT.gov ↗
92. NCT01579760

    Aflibercept every 2 months

    Phase 1 · completed · small_molecule

    Radiation Retinopathy

    CT.gov ↗
93. NCT01604824

    Alirocumab

    Phase 3 · active · small_molecule

    Hypercholesterolemia

    CT.gov ↗
94. NCT01605708

    REGN846

    Phase 2 · terminated · small_molecule

    Pruritus

    CT.gov ↗
95. NCT01617148

    Aflibercept

    Approved · completed · small_molecule

    Exudative Macular Degeneration

    CT.gov ↗
96. NCT01617655

    Alirocumab

    Phase 3 · completed · small_molecule

    Hypercholesterolaemia

    CT.gov ↗
97. NCT01623115

    Alirocumab

    Phase 3 · active · small_molecule

    Hypercholesterolemia

    CT.gov ↗
98. NCT01627249

    2.0 mg intravitreal aflibercept

    Phase 3 · completed · small_molecule

    Diabetic Macular Edema

    CT.gov ↗
99. NCT01639040

    Dupilumab

    Approved · active · small_molecule

    Atopic Dermatitis

    CT.gov ↗
100. NCT01644175

     Placebo (for alirocumab)

     Phase 3 · completed · small_molecule

     Hypercholesterolemia

     CT.gov ↗
101. NCT01644188

     Alirocumab

     Phase 3 · active · small_molecule

     Hypercholesterolemia

     CT.gov ↗
102. NCT01644474

     Alirocumab

     Phase 3 · active · small_molecule

     Hypercholesterolemia

     CT.gov ↗
103. NCT01661270

     Aflibercept

     Phase 3 · completed · small_molecule

     Colorectal Cancer Metastatic

     CT.gov ↗
104. NCT01663402

     Alirocumab

     Phase 3 · completed · small_molecule

     Atherosclerotic Cardiovascular Disease

     CT.gov ↗
105. NCT01670162

     Aflibercept

     Approved · active · small_molecule

     Age Related Macular Degeneration

     CT.gov ↗
106. NCT01670721

     Aflibercept

     Phase 3 · completed · small_molecule

     Colorectal Cancer Metastatic

     CT.gov ↗
107. NCT01670734

     alirocumab SAR236553 (REGN727)

     Phase 3 · completed · small_molecule

     Hypercholesterolemia

     CT.gov ↗
108. NCT01688960

     nesvacumab (REGN910/ SAR307746)

     Phase 1 · completed · small_molecule

     Solid Tumors

     CT.gov ↗
109. NCT01709500

     R727-CL-1112

     Phase 3 · completed · small_molecule

     Heterozygous Familial Hypercholesterolemia

     CT.gov ↗
110. NCT01709513

     Atorvastatin

     Phase 3 · completed · small_molecule

     Hypercholesterolemia

     CT.gov ↗
111. NCT01709578

     Sarilumab

     Approved · terminated · small_molecule

     Rheumatoid Arthritis

     CT.gov ↗
112. NCT01710332

     Intravitreal Aflibercept Injection

     Phase 2 · completed · small_molecule

     Central Serous Chorioretinopathy

     CT.gov ↗
113. NCT01720576

     REGN1033 (SAR391786)

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
114. NCT01722045

     Intravitreal Aflibercept Injection (IAI)

     Approved · completed · small_molecule

     Age - Related Macular Degeneration (AMD)

     CT.gov ↗
115. NCT01722656

     Aflibercept

     Approved · completed · small_molecule

     Submacular Vascularized Pigment Epithelial Detachments

     CT.gov ↗
116. NCT01723735

     Alirocumab

     Phase 3 · active · small_molecule

     Hypercholesterolemia

     CT.gov ↗
117. NCT01724554

     Intravitreal Aflibercept Injection

     Phase 2 · completed · small_molecule

     Central Retinal Vein Occlusion

     CT.gov ↗
118. NCT01727869

     REGN1400

     Phase 1 · completed · small_molecule

     Cancer

     CT.gov ↗
119. NCT01730040

     Alirocumab

     Phase 3 · active · small_molecule

     Hypercholesterolemia

     CT.gov ↗
120. NCT01730053

     Alirocumab

     Phase 3 · active · small_molecule

     Hypercholesterolemia

     CT.gov ↗
121. NCT01749878

     REGN1500

     Phase 1 · completed · small_molecule

     Hypertriglyceridemia

     CT.gov ↗
122. NCT01764997

     Sarilumab

     Approved · terminated · small_molecule

     Rheumatoid Arthritis

     CT.gov ↗
123. NCT01768572

     sarilumab SAR153191 (REGN88)

     Phase 3 · completed · small_molecule

     Rheumatoid Arthritis

     CT.gov ↗
124. NCT01773954

     Intravitreal Aflibercept Injection

     Phase 2 · completed · small_molecule

     Age-Related Macular Degeneration

     CT.gov ↗
125. NCT01783886

     15161

     Phase 3 · completed · mab

     Macular Edema

     CT.gov ↗
126. NCT01785329

     alirocumab SAR236553 (REGN727)

     Phase 3 · completed · small_molecule

     Hypercholesterolemia

     CT.gov ↗
127. NCT01803321

     rilonacept (IL-1 Trap)

     Phase 1 · completed · small_molecule

     Systemic Juvenile Idiopathic Arthritis

     CT.gov ↗
128. NCT01812707

     Alirocumab

     Phase 3 · active · small_molecule

     Hypercholesterolemia

     CT.gov ↗
129. NCT01813773

     Intravitreal Aflibercept Injection (IAI)

     Phase 3 · completed · small_molecule

     Proliferative Diabetic Retinopathy

     CT.gov ↗
130. NCT01850680

     sarilumab SAR153191 (REGN88)

     Phase 3 · completed · small_molecule

     Rheumatoid Arthritis

     CT.gov ↗
131. NCT01854047

     Dupilumab

     Approved · active · small_molecule

     Asthma

     CT.gov ↗
132. NCT01857544

     Aflibercept

     Approved · active · small_molecule

     Retinal Vein Occlusion

     CT.gov ↗
133. NCT01859988

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
134. NCT01868360

     Subconjunctival aflibercept

     Phase 1 · terminated · small_molecule

     Corneal Neovascularization

     CT.gov ↗
135. NCT01870427

     Aflibercept (2.0 mg)

     Approved · completed · small_molecule

     Macular Edema With Central Retinal Vein Occlusions

     CT.gov ↗
136. NCT01871376

     Intravitreal aflibercept injection 2.0mg

     Approved · completed · small_molecule

     Polypoidal Choroidal Vasculopathy

     CT.gov ↗
137. NCT01882868

     Aflibercept

     Phase 3 · completed · small_molecule

     Colorectal Cancer Metastatic

     CT.gov ↗
138. NCT01893528

     REGN2009

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
139. NCT01909791

     Prompt aflibercept

     Phase 3 · completed · small_molecule

     Diabetic Macular Edema

     CT.gov ↗
140. NCT01910220

     REGN1033 (SAR391786)

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
141. NCT01920893

     Placebo (for dupilumab)

     Phase 2 · completed · small_molecule

     Nasal Polyps

     CT.gov ↗
142. NCT01922661

     REGN1908-1909

     Phase 1 · completed · small_molecule

     Allergy

     CT.gov ↗
143. NCT01926782

     Placebo (for alirocumab)

     Phase 3 · completed · small_molecule

     Hypercholesterolemia

     CT.gov ↗
144. NCT01930552

     Aflibercept (AVE0005)

     Phase 1 · completed · small_molecule

     Neoplasm Malignant

     CT.gov ↗
145. NCT01933763

     REGN1193

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
146. NCT01949311

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
147. NCT01954394

     Alirocumab

     Phase 3 · active · small_molecule

     Hypercholesterolemia

     CT.gov ↗
148. NCT01955629

     Aflibercept AVE0005

     Phase 3 · terminated · small_molecule

     Colorectal Cancer Metastatic

     CT.gov ↗
149. NCT01959971

     Alirocumab

     Phase 3 · active · small_molecule

     Hypercholesterolemia

     CT.gov ↗
150. NCT01963598

     REGN1033 (SAR391786)

     Phase 2 · completed · small_molecule

     Sarcopenia

     CT.gov ↗
151. NCT01979016

     Dupilumab

     Approved · terminated · small_molecule

     Atopic Dermatitis (AD)

     CT.gov ↗
152. NCT01988246

     Aflibercept

     Approved · completed · small_molecule

     Diabetic Retinopathy

     CT.gov ↗
153. NCT01997164

     REGN910-3

     Phase 2 · completed · small_molecule

     Neovascular Age-Related Macular Degeneration

     CT.gov ↗
154. NCT02017639

     sarilumab SAR153191 (REGN88)

     Phase 3 · completed · small_molecule

     Rheumatoid Arthritis

     CT.gov ↗
155. NCT02023879

     Alirocumab

     Phase 3 · active · small_molecule

     Hypercholesterolemia

     CT.gov ↗
156. NCT02045030

     aflibercept + FOLFIRI

     Phase 2 · terminated · small_molecule

     Metastatic Colorectal Cancer

     CT.gov ↗
157. NCT02057250

     Sarilumab

     Phase 3 · completed · small_molecule

     RA

     CT.gov ↗
158. NCT02061865

     REGN2176-3

     Phase 1 · completed · small_molecule

     Neovascular Wet Age-related Macular Degeneration (AMD)

     CT.gov ↗
159. NCT02085005

     Capecitabine

     Phase 2 · terminated · small_molecule

     Colorectal Cancer Metastatic

     CT.gov ↗
160. NCT02092532

     Rescue Intravitreal Aflibercept Injection

     Approved · active · small_molecule

     Neovascular Polypoidal Choroidal Vasculopathy

     CT.gov ↗
161. NCT02097524

     Sarilumab

     Approved · terminated · small_molecule

     Rheumatoid Arthritis

     CT.gov ↗
162. NCT02107872

     REGN1500

     Phase 1 · completed · small_molecule

     Metabolic Disorders

     CT.gov ↗
163. NCT02107898

     Placebo (for alirocumab)

     Phase 3 · completed · small_molecule

     Hypercholesterolemia

     CT.gov ↗
164. NCT02120950

     16995

     Approved · completed · small_molecule

     Neovascular Macular Degeneration

     CT.gov ↗
165. NCT02121080

     REGN2222(SAR438584)

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
166. NCT02121210

     sarilumab SAR153191 (REGN88)

     Phase 3 · completed · small_molecule

     Rheumatoid Arthritis

     CT.gov ↗
167. NCT02127801

     REGN1908-1909

     Phase 1 · completed · small_molecule

     Allergy

     CT.gov ↗
168. NCT02134028

     Dupilumab

     Approved · active · small_molecule

     Asthma

     CT.gov ↗
169. NCT02171416

     Rilonacept

     Phase 2 · completed · small_molecule

     Cold Contact Urticaria

     CT.gov ↗
170. NCT02204683

     Aflibercept

     Phase 1 · completed · small_molecule

     Neovascular Macular Degeneration

     CT.gov ↗
171. NCT02210780

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
172. NCT02260986

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
173. NCT02265952

     REGN1500 250 mg SC/15 mg/kg IV/450 mg SC

     Phase 2 · completed · small_molecule

     Homozygous Familial Hypercholesterolemia

     CT.gov ↗
174. NCT02277743

     Dupilumab

     Approved · active · small_molecule

     Dermatitis, Atopic

     CT.gov ↗
175. NCT02277769

     Dupilumab

     Approved · active · small_molecule

     Dermatitis, Atopic

     CT.gov ↗
176. NCT02284425

     REGN1193

     Phase 1 · terminated · small_molecule

     Diabetes Mellitus, Type 2

     CT.gov ↗
177. NCT02289963

     Placebo (for alirocumab)

     Phase 3 · completed · small_molecule

     Hypercholesterolemia

     CT.gov ↗
178. NCT02290951

     Odronextamab multiple dose levels

     Phase 1 · completed · small_molecule

     Non-Hodgkin Lymphoma

     CT.gov ↗
179. NCT02293902

     sarilumab SAR153191 (REGN88)

     Phase 3 · completed · small_molecule

     Rheumatoid Arthritis

     CT.gov ↗
180. NCT02297204

     aflibercept 2.0 mg

     Approved · completed · small_molecule

     Diabetic Macular Edema

     CT.gov ↗
181. NCT02299336

     Aflibercept

     Approved · completed · small_molecule

     Diabetic Macular Edema

     CT.gov ↗
182. NCT02305238

     17668

     Approved · completed · small_molecule

     Wet Macular Degeneration

     CT.gov ↗
183. NCT02325791

     Suptavumab 30 mg/kg

     Phase 3 · completed · small_molecule

     Respiratory Syncytial Virus Infections

     CT.gov ↗
184. NCT02326220

     Placebo

     Phase 3 · completed · small_molecule

     Heterozygous Familial Hypercholesterolemia

     CT.gov ↗
185. NCT02332590

     Sarilumab

     Approved · terminated · small_molecule

     Rheumatoid Arthritis

     CT.gov ↗
186. NCT02373202

     Sarilumab

     Approved · terminated · small_molecule

     Rheumatoid Arthritis

     CT.gov ↗
187. NCT02379052

     Dupilumab

     Approved · active · small_molecule

     Eosinophilic Esophagitis

     CT.gov ↗
188. NCT02383212

     Cemiplimab

     Phase 1 · completed · small_molecule

     Advanced Cancer

     CT.gov ↗
189. NCT02392364

     Intravitreal Aflibercept Injection

     Approved · completed · small_molecule

     Cystoid Macular Edema

     CT.gov ↗
190. NCT02395133

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
191. NCT02396316

     Aflibercept (Eylea, BAY 86-5321)

     Phase 3 · completed · small_molecule

     Glaucoma, Neovascular

     CT.gov ↗
192. NCT02404558

     sarilumab SAR153191 (REGN88)

     Phase 3 · completed · small_molecule

     Rheumatoid Arthritis

     CT.gov ↗
193. NCT02407756

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
194. NCT02414854

     Dupilumab

     Approved · active · small_molecule

     Asthma

     CT.gov ↗
195. NCT02418754

     REGN2176-3

     Phase 2 · terminated · small_molecule

     Neovascular Age-Related Macular Degeneration

     CT.gov ↗
196. NCT02447276

     REGN475

     Phase 3 · completed · small_molecule

     Osteoarthritis, Knee

     CT.gov ↗
197. NCT02462889

     Intravitreal Aflibercept Injection

     Phase 2 · completed · small_molecule

     Age-Related Macular Degeneration

     CT.gov ↗
198. NCT02476006

     alirocumab SAR236553 (REGN727)

     Phase 3 · completed · small_molecule

     Hypercholesterolemia

     CT.gov ↗
199. NCT02503540

     Aflibercept

     Approved · active · small_molecule

     Retinal Vein Occlusion

     CT.gov ↗
200. NCT02516618

     Fasinumab

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
201. NCT02520245

     REGN2810

     Phase 1 · terminated · small_molecule

     Advanced Malignancies

     CT.gov ↗
202. NCT02528214

     Dupilumab

     Approved · active · small_molecule

     Asthma

     CT.gov ↗
203. NCT02559180

     Aflibercept

     Approved · completed · small_molecule

     Diabetic Retinopathy

     CT.gov ↗
204. NCT02573233

     Placebo

     Phase 2 · completed · small_molecule

     Asthma

     CT.gov ↗
205. NCT02581891

     17508

     Approved · completed · small_molecule

     Macular Degeneration

     CT.gov ↗
206. NCT02584504

     Alirocumab

     Phase 3 · active · small_molecule

     Hypercholesterolemia

     CT.gov ↗
207. NCT02585778

     Alirocumab

     Phase 3 · completed · small_molecule

     Hypercholesterolaemia

     CT.gov ↗
208. NCT02612454

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
209. NCT02620020

     Fasinumab

     Phase 3 · completed · small_molecule

     Low Back Pain

     CT.gov ↗
210. NCT02634333

     Prompt aflibercept

     Phase 3 · completed · small_molecule

     Diabetic Retinopathy

     CT.gov ↗
211. NCT02642159

     Alirocumab

     Approved · completed · small_molecule

     Dyslipidemia

     CT.gov ↗
212. NCT02647086

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
213. NCT02651662

     cemiplimab

     Phase 1 · active · small_molecule

     Relapsed/Refractory Aggressive B-Cell Lymphoma

     CT.gov ↗
214. NCT02680184

     CMP-001

     Phase 3 · completed · small_molecule

     Melanoma

     CT.gov ↗
215. NCT02683239

     Fasinumab

     Phase 3 · completed · small_molecule

     Osteoarthritis of the Knee or Hip

     CT.gov ↗
216. NCT02689518

     Intravitreal aflibercept injection

     Approved · completed · small_molecule

     Macular Degeneration

     CT.gov ↗
217. NCT02712008

     REGN910-3

     Phase 2 · completed · small_molecule

     Diabetic Macular Edema

     CT.gov ↗
218. NCT02713204

     REGN910-3

     Phase 2 · completed · small_molecule

     Neovascular Age-Related Macular Degeneration

     CT.gov ↗
219. NCT02715726

     Alirocumab

     Phase 3 · active · small_molecule

     Hypercholesterolemia

     CT.gov ↗
220. NCT02718326

     Intravitreal aflibercept injection [IAI]

     Phase 3 · completed · small_molecule

     Nonproliferative Diabetic Retinopathy

     CT.gov ↗
221. NCT02741739

     REGN1033

     Phase 1 · completed · small_molecule

     Healthy

     CT.gov ↗
222. NCT02744287

     BPX-601

     Phase 1 · terminated · mab

     Metastatic Castration-resistant Prostate Cancer

     CT.gov ↗
223. NCT02755649

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
224. NCT02760498

     cemiplimab

     Phase 2 · completed · small_molecule

     Advanced Cutaneous Squamous Cell Carcinoma

     CT.gov ↗
225. NCT02776735

     Sarilumab

     Phase 2 · completed · small_molecule

     Juvenile Idiopathic Arthritis

     CT.gov ↗
226. NCT02777151

     REGN3470-3471-3479

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
227. NCT02828033

     Rilonacept

     Phase 1 · active · small_molecule

     Autoimmune Neurosensory Hearing Loss (ANSHL)

     CT.gov ↗
228. NCT02828397

     REGN2222

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
229. NCT02858076

     2-mg Intravitreous Aflibercept Injection

     Phase 3 · completed · small_molecule

     Proliferative Diabetic Retinopathy

     CT.gov ↗
230. NCT02863354

     Aflibercept

     Phase 2 · completed · small_molecule

     Proliferative Diabetic Retinopathy

     CT.gov ↗
231. NCT02870400

     REGN2477

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
232. NCT02890992

     alirocumab SAR236553 (REGN727)

     Phase 3 · completed · small_molecule

     Hypercholesterolaemia

     CT.gov ↗
233. NCT02898454

     Dupilumab SAR231893 (REGN668)

     Phase 3 · completed · small_molecule

     Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

     CT.gov ↗
234. NCT02912468

     Dupilumab SAR231893 (REGN668)

     Phase 3 · completed · small_molecule

     Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

     CT.gov ↗
235. NCT02938949

     Alirocumab

     Approved · terminated · small_molecule

     Myocardial Infarction

     CT.gov ↗
236. NCT02943239

     REGN1033

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
237. NCT02948959

     Dupilumab

     Approved · active · small_molecule

     Asthma

     CT.gov ↗
238. NCT02957682

     Praluent (Alirocumab)

     Approved · completed · small_molecule

     Hypercholesterolemia

     CT.gov ↗
239. NCT02958436

     REGN3500

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
240. NCT02979015

     alirocumab SAR236553 (REGN727)

     Phase 3 · completed · small_molecule

     Hypercholesterolemia

     CT.gov ↗
241. NCT02984982

     Alirocumab SAR236553

     Approved · completed · small_molecule

     Hypercholesterolemia

     CT.gov ↗
242. NCT02991469

     Sarilumab SAR153191 (REGN88)

     Phase 2 · active · small_molecule

     Juvenile Idiopathic Arthritis

     CT.gov ↗
243. NCT02992301

     Alirocumab

     Approved · active · small_molecule

     Atherosclerosis

     CT.gov ↗
244. NCT02999711

     REGN3500

     Phase 1 · completed · small_molecule

     Asthma

     CT.gov ↗
245. NCT03002376

     REGN2810

     Phase 1 · completed · small_molecule

     Melanoma

     CT.gov ↗
246. NCT03004001

     Alirocumab

     Phase 2 · terminated · small_molecule

     Nephrotic Syndrome

     CT.gov ↗
247. NCT03005782

     REGN3767

     Phase 1 · completed · small_molecule

     Malignancies

     CT.gov ↗
248. NCT03022292

     Aflibercept Ophthalmic

     Approved · completed · small_molecule

     Wet Macular Degeneration

     CT.gov ↗
249. NCT03050151

     Dupilumab

     Phase 1 · completed · small_molecule

     Atopic Disorders

     CT.gov ↗
250. NCT03054428

     Dupilumab

     Approved · completed · small_molecule

     Moderate-to-Severe Atopic Dermatitis

     CT.gov ↗
251. NCT03059277

     Intravitreal Aflibercept

     Approved · terminated · small_molecule

     Diabetic Macular Edema

     CT.gov ↗
252. NCT03067844

     Alirocumab

     Phase 3 · completed · small_molecule

     Coronary Vessel

     CT.gov ↗
253. NCT03084640

     CMP-001

     Phase 1 · completed · small_molecule

     Malignant Melanoma

     CT.gov ↗
254. NCT03085784

     Aflibercept

     Phase 2 · active · small_molecule

     Radiation Retinopathy

     CT.gov ↗
255. NCT03088540

     Pemetrexed

     Phase 3 · completed · small_molecule

     Carcinoma，Non-Small-Cell Lung

     CT.gov ↗
256. NCT03112577

     REGN3500

     Phase 1 · completed · small_molecule

     Asthma, Allergic

     CT.gov ↗
257. NCT03115996

     REGN3918

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
258. NCT03132636

     cemiplimab

     Phase 2 · completed · small_molecule

     Carcinoma, Basal Cell

     CT.gov ↗
259. NCT03146416

     Evinacumab

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
260. NCT03156621

     Alirocumab

     Phase 3 · completed · small_molecule

     Homozygous Familial Hypercholesterolemia

     CT.gov ↗
261. NCT03161093

     Fasinumab

     Phase 3 · completed · small_molecule

     Osteoarthritis, Knee

     CT.gov ↗
262. NCT03175367

     Evinacumab

     Phase 2 · completed · small_molecule

     Hypercholesterolemia

     CT.gov ↗
263. NCT03188666

     REGN2477

     Phase 2 · completed · small_molecule

     Fibrodysplasia Ossificans Progressiva

     CT.gov ↗
264. NCT03198130

     REGN2810

     Phase 1 · completed · small_molecule

     Recurrent Squamous Cell Carcinoma of Head

     CT.gov ↗
265. NCT03233139

     Cemiplimab

     Phase 1 · active · small_molecule

     Advanced Malignancies

     CT.gov ↗
266. NCT03257267

     Cemiplimab

     Phase 3 · completed · small_molecule

     Squamous Cell Carcinoma (SCC)

     CT.gov ↗
267. NCT03285646

     Fasinumab

     Phase 3 · terminated · small_molecule

     Chronic Low Back Pain

     CT.gov ↗
268. NCT03293030

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
269. NCT03294083

     Pexastimogene Devacirepvec (Pexa-Vec)

     Phase 2 · active · mab

     Renal Cell Carcinoma

     CT.gov ↗
270. NCT03304379

     Fasinumab

     Phase 3 · completed · small_molecule

     Osteoarthritis, Knee

     CT.gov ↗
271. NCT03344692

     Alirocumab

     Phase 3 · completed · small_molecule

     Type2 Diabetes

     CT.gov ↗
272. NCT03345914

     Dupilumab

     Approved · active · small_molecule

     Dermatitis, Atopic

     CT.gov ↗
273. NCT03346434

     Dupilumab

     Approved · active · small_molecule

     Dermatitis, Atopic

     CT.gov ↗
274. NCT03359356

     Dupilumab

     Phase 2 · active · small_molecule

     Alopecia Areata

     CT.gov ↗
275. NCT03387852

     SAR440340

     Phase 2 · completed · small_molecule

     Asthma

     CT.gov ↗
276. NCT03389893

     Dupilumab

     Approved · terminated · small_molecule

     Atopic Dermatitis (AD)

     CT.gov ↗
277. NCT03396861

     Aflibercept

     Phase 1 · terminated · small_molecule

     Irvine-Gass Syndrome

     CT.gov ↗
278. NCT03399786

     evinacumab

     Phase 3 · completed · small_molecule

     Homozygous Familial Hypercholesterolemia

     CT.gov ↗
279. NCT03409614

     REGN2810

     Phase 3 · completed · small_molecule

     Non-small Cell Lung Cancer

     CT.gov ↗
280. NCT03409744

     evinacumab

     Phase 3 · completed · small_molecule

     Homozygous Familial Hypercholesterolemia

     CT.gov ↗
281. NCT03415178

     Alirocumab SAR236553

     Phase 3 · completed · small_molecule

     Hypercholesterolaemia

     CT.gov ↗
282. NCT03430063

     SDREGN2810

     Phase 2 · terminated · small_molecule

     Advanced Non-Small Cell Lung Carcinoma

     CT.gov ↗
283. NCT03438318

     CMP-001

     Phase 1 · completed · small_molecule

     Non Small Cell Lung Cancer

     CT.gov ↗
284. NCT03449758

     Sarilumab

     Approved · terminated · small_molecule

     Rheumatoid Arthritis

     CT.gov ↗
285. NCT03452228

     evinacumab

     Phase 2 · completed · small_molecule

     Severe Hypertriglyceridemia (sHTG)

     CT.gov ↗
286. NCT03468296

     Intravitreal Aflibercept Injection 2mg

     Approved · active · small_molecule

     Neovascular Age-related Macular Degeneration

     CT.gov ↗
287. NCT03477864

     Ipilimumab

     Phase 1 · terminated · mab

     Stage III Prostate Cancer

     CT.gov ↗
288. NCT03480568

     Alirocumab 150 MG/ML [Praluent]

     Phase 3 · active · small_molecule

     Hemodialysis

     CT.gov ↗
289. NCT03491904

     Fasinumab AI

     Phase 1 · completed · small_molecule

     Osteoarthritis, Knee

     CT.gov ↗
290. NCT03507374

     Alirocumab

     Phase 1 · terminated · small_molecule

     Stroke

     CT.gov ↗
291. NCT03510715

     alirocumab SAR236553 (REGN727)

     Phase 3 · completed · small_molecule

     Hypercholesterolemia

     CT.gov ↗
292. NCT03510884

     alirocumab SAR236553 (REGN727)

     Phase 3 · completed · small_molecule

     Hypercholesterolaemia

     CT.gov ↗
293. NCT03515629

     REGN2810/ipi

     Phase 3 · terminated · small_molecule

     Non-small Cell Lung Cancer

     CT.gov ↗
294. NCT03530514

     REGN4461

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
295. NCT03531294

     Aflibercept Injection

     Approved · completed · small_molecule

     Diabetic Retinopathy

     CT.gov ↗
296. NCT03542110

     Alirocumab 150 MG/ML subcutaneous injection

     Approved · terminated · small_molecule

     Saphenous Vein Graft Atherosclerosis

     CT.gov ↗
297. NCT03546907

     SAR440340

     Phase 2 · completed · small_molecule

     Chronic Obstructive Pulmonary Disease

     CT.gov ↗
298. NCT03558997

     Dupilumab

     Phase 2 · completed · small_molecule

     Allergic Rhinitis

     CT.gov ↗
299. NCT03560466

     Dupilumab SAR231893 (REGN668)

     Phase 3 · completed · small_molecule

     Asthma

     CT.gov ↗
300. NCT03564340

     Ubamatamab

     Phase 2 · active · small_molecule

     Recurrent Ovarian Cancer

     CT.gov ↗
301. NCT03580694

     REGN4659

     Phase 1 · terminated · small_molecule

     Carcinoma, Non-Small-Cell Lung

     CT.gov ↗
302. NCT03600805

     Sarilumab SAR153191

     Phase 3 · terminated · small_molecule

     Giant Cell Arteritis

     CT.gov ↗
303. NCT03600818

     Sarilumab SAR153191 (REGN88)

     Phase 3 · terminated · small_molecule

     Polymyalgia Rheumatica

     CT.gov ↗
304. NCT03620747

     Dupilumab SAR231893 (REGN668)

     Phase 3 · completed · small_molecule

     Asthma

     CT.gov ↗
305. NCT03633617

     Dupilumab

     Approved · active · small_molecule

     Eosinophilic Esophagitis

     CT.gov ↗
306. NCT03639675

     Aflibercept (EYLEA, BAY86-5321)

     Phase 3 · completed · small_molecule

     Glaucoma, Neovascular

     CT.gov ↗
307. NCT03645746

     REGN5069

     Phase 1 · completed · small_molecule

     Healthy Volunteer

     CT.gov ↗
308. NCT03667014

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
309. NCT03669718

     ISA101b

     Phase 2 · active · mab

     Squamous Cell Carcinoma of the Oropharynx

     CT.gov ↗
310. NCT03678545

     Dupilumab (blinded)

     Phase 2 · completed · small_molecule

     Eosinophilic Gastritis

     CT.gov ↗
311. NCT03679845

     Sarilumab

     Phase 2 · terminated · small_molecule

     Morphea, Plaque Form

     CT.gov ↗
312. NCT03682770

     Dupilumab

     Phase 2 · completed · small_molecule

     Peanut Allergy

     CT.gov ↗
313. NCT03690869

     cemiplimab (monotherapy)

     Phase 2 · terminated · small_molecule

     Relapsed Solid Tumor

     CT.gov ↗
314. NCT03691974

     Fasinumab

     Phase 3 · completed · small_molecule

     Osteoarthritis, Knee

     CT.gov ↗
315. NCT03694158

     Dupilumab

     Approved · active · small_molecule

     Asthma

     CT.gov ↗
316. NCT03694197

     Praluent

     Approved · terminated · small_molecule

     Heterozygous Familial Hypercholesterolemia

     CT.gov ↗
317. NCT03710941

     REGN2477+REGN1033

     Phase 2 · terminated · small_molecule

     Sporadic Inclusion Body Myositis

     CT.gov ↗
318. NCT03712904

     Ziv-Aflibercept

     Phase 2 · terminated · mab

     Uveal Melanoma

     CT.gov ↗
319. NCT03736967

     REGN3500

     Phase 2 · terminated · small_molecule

     Atopic Dermatitis

     CT.gov ↗
320. NCT03738423

     REGN3500

     Phase 2 · terminated · small_molecule

     Atopic Dermatitis

     CT.gov ↗
321. NCT03746704

     89Zr˗DFO˗REGN3504

     Phase 1 · terminated · small_molecule

     Advanced PD-L1 Positive Malignancies

     CT.gov ↗
322. NCT03750760

     Alirocumab

     Approved · terminated · small_molecule

     Myocardial Infarction

     CT.gov ↗
323. NCT03761108

     Linvoseltamab

     Phase 3 · active · small_molecule

     Multiple Myeloma

     CT.gov ↗
324. NCT03767738

     Intravitreal Aflibercept Injection (IAI)

     Approved · completed · small_molecule

     Chorioretinal Vascular Disease

     CT.gov ↗
325. NCT03782532

     Dupilumab SAR231893

     Phase 3 · completed · small_molecule

     Asthma

     CT.gov ↗
326. NCT03787095

     Cemiplimab

     Phase 2 · terminated · mab

     HIV Infections

     CT.gov ↗
327. NCT03793608

     Dupilumab

     Phase 2 · completed · small_molecule

     Peanut Allergy

     CT.gov ↗
328. NCT03838731

     REGN1908-1909

     Phase 2 · completed · small_molecule

     Cat Allergy

     CT.gov ↗
329. NCT03886493

     Dupilumab

     Phase 2 · terminated · small_molecule

     Prostate Cancer

     CT.gov ↗
330. NCT03888105

     Odronextamab

     Phase 2 · active · small_molecule

     B-cell Non-Hodgkin Lymphoma (B-NHL)

     CT.gov ↗
331. NCT03889912

     Cemiplimab

     Phase 3 · active · small_molecule

     Cutaneous Squamous Cell Carcinoma

     CT.gov ↗
332. NCT03912259

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
333. NCT03916627

     cemiplimab

     Phase 3 · active · small_molecule

     Non-small Cell Lung Cancer

     CT.gov ↗
334. NCT03930732

     Dupilumab SAR231893

     Phase 3 · completed · small_molecule

     Chronic Obstructive Pulmonary Disease

     CT.gov ↗
335. NCT03935971

     Dupilumab

     Approved · active · small_molecule

     Allergic Contact Dermatitis

     CT.gov ↗
336. NCT03946748

     REGN3918

     Phase 2 · completed · small_molecule

     Paroxysmal Nocturnal Hemoglobinuria (PNH)

     CT.gov ↗
337. NCT03949673

     Fasinumab

     Phase 3 · completed · small_molecule

     Osteoarthritis, Knee

     CT.gov ↗
338. NCT03951831

     REGN2810

     Phase 2 · active · small_molecule

     Prostate Cancer Metastatic

     CT.gov ↗
339. NCT03956550

     REGN5069

     Phase 2 · terminated · small_molecule

     Osteoarthritis of the Knee

     CT.gov ↗
340. NCT03969004

     Cemiplimab

     Phase 3 · active · small_molecule

     Cutaneous Squamous Cell Carcinoma

     CT.gov ↗
341. NCT03969849

     REGN5713-5714-5715

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
342. NCT03972657

     REGN5678

     Phase 2 · active · small_molecule

     Metastatic Castration-Resistant Prostate Cancer (mCRPC)

     CT.gov ↗
343. NCT04004208

     Eylea (Aflibercept, BAY86-5321)

     Phase 3 · completed · small_molecule

     Retinopathy of Prematurity (ROP)

     CT.gov ↗
344. NCT04015180

     Eylea (Aflibercept, BAY86-5321)

     Phase 3 · completed · small_molecule

     Retinopathy of Prematurity (ROP)

     CT.gov ↗
345. NCT04033367

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
346. NCT04046107

     Cemiplimab

     Phase 2 · terminated · mab

     Hepatitis B Virus

     CT.gov ↗
347. NCT04050436

     Cemiplimab

     Phase 3 · active · small_molecule

     Cutaneous Squamous Cell Carcinoma

     CT.gov ↗
348. NCT04077099

     REGN5093

     Phase 2 · active · small_molecule

     NSCLC

     CT.gov ↗
349. NCT04083534

     REGN5459

     Phase 2 · completed · small_molecule

     Relapsed Multiple Myeloma

     CT.gov ↗
350. NCT04101721

     aflibercept

     Phase 3 · completed · small_molecule

     Retinopathy of Prematurity

     CT.gov ↗
351. NCT04126317

     aflibercept

     Phase 2 · completed · small_molecule

     Neovascular (Wet) Age-Related Macular Degeneration

     CT.gov ↗
352. NCT04148352

     Dupilumab

     Phase 2 · terminated · small_molecule

     Allergies Food Milk

     CT.gov ↗
353. NCT04154943

     Cemiplimab

     Phase 3 · active · small_molecule

     Cutaneous Squamous Cell Carcinoma

     CT.gov ↗
354. NCT04159415

     Placebo

     Phase 2 · completed · small_molecule

     Generalized Lipodystrophy

     CT.gov ↗
355. NCT04162470

     REGN3918

     Phase 3 · terminated · small_molecule

     Paroxysmal Nocturnal Hemoglobinuria

     CT.gov ↗
356. NCT04180488

     Dupilumab SAR231893

     Phase 3 · completed · small_molecule

     Chronic Spontaneous Urticaria

     CT.gov ↗
357. NCT04183335

     Dupilumab SAR231893

     Phase 3 · completed · small_molecule

     Neurodermatitis

     CT.gov ↗
358. NCT04202679

     Dupilumab SAR231893

     Phase 3 · completed · small_molecule

     Neurodermatitis

     CT.gov ↗
359. NCT04203797

     Dupilumab

     Approved · active · small_molecule

     Asthma

     CT.gov ↗
360. NCT04206553

     dupilumab

     Phase 3 · completed · small_molecule

     Bullous Pemphigoid

     CT.gov ↗
361. NCT04209634

     Pozelimab

     Phase 3 · completed · small_molecule

     CD55-deficient Protein-losing Enteropathy

     CT.gov ↗
362. NCT04233918

     evinacumab

     Phase 3 · completed · small_molecule

     Homozygous Familial Hypercholesterolemia

     CT.gov ↗
363. NCT04242173

     Cemiplimab-Rwlc

     Phase 2 · terminated · small_molecule

     Cutaneous Squamous Cell Carcinoma

     CT.gov ↗
364. NCT04256759

     Dupilumab 300Mg Solution for Injection

     Phase 2 · completed · small_molecule

     Pruritus

     CT.gov ↗
365. NCT04291105

     VV1

     Phase 2 · active · mab

     Melanoma

     CT.gov ↗
366. NCT04296864

     Dupilumab

     Phase 2 · active · small_molecule

     Atopic Keratoconjunctivitis

     CT.gov ↗
367. NCT04311606

     Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept

     Phase 2 · completed · small_molecule

     Thyroid Eye Disease

     CT.gov ↗
368. NCT04315298

     Sarilumab

     Phase 3 · completed · small_molecule

     COVID-19

     CT.gov ↗
369. NCT04327388

     Sarilumab SAR153191

     Phase 3 · completed · small_molecule

     Corona Virus Infection

     CT.gov ↗
370. NCT04339062

     Cemiplimab

     Phase 3 · active · small_molecule

     Cutaneous Squamous Cell Carcinoma

     CT.gov ↗
371. NCT04362501

     dupilumab

     Phase 2 · completed · mab

     Chronic Sinusitis

     CT.gov ↗
372. NCT04373083

     Cemiplimab

     Phase 2 · terminated · small_molecule

     Hodgkin Lymphoma

     CT.gov ↗
373. NCT04380038

     Dupilumab Injectable Product

     Approved · active · small_molecule

     Asthma

     CT.gov ↗
374. NCT04394351

     Dupilumab

     Phase 3 · active · small_molecule

     Eosinophilic Esophagitis (EoE)

     CT.gov ↗
375. NCT04398524

     ISA101b

     Phase 2 · active · mab

     Squamous Cell Carcinoma of the Oropharynx

     CT.gov ↗
376. NCT04400318

     Dupilumab

     Approved · active · small_molecule

     Asthma

     CT.gov ↗
377. NCT04409080

     REGN7257

     Phase 1 · terminated · small_molecule

     Severe Aplastic Anemia (SAA)

     CT.gov ↗
378. NCT04417894

     dupilumab

     Phase 3 · completed · small_molecule

     Moderate to Severe Atopic Hand and Foot Dermatitis

     CT.gov ↗
379. NCT04423718

     Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

     Phase 3 · completed · small_molecule

     Neovascular Age-Related Macular Degeneration

     CT.gov ↗
380. NCT04425629

     casirivimab+imdevimab combination therapy

     Phase 3 · terminated · small_molecule

     COVID-19

     CT.gov ↗
381. NCT04426695

     REGN10933+REGN10987 combination therapy

     Phase 2 · completed · small_molecule

     COVID-19

     CT.gov ↗
382. NCT04429503

     Aflibercept

     Approved · completed · small_molecule

     Diabetic Macular Edema

     CT.gov ↗
383. NCT04442269

     dupilumab

     Phase 2 · completed · small_molecule

     Allergic Bronchopulmonary Aspergillosis

     CT.gov ↗
384. NCT04447417

     Dupilumab SAR231893

     Approved · completed · small_molecule

     Atopic Dermatitis

     CT.gov ↗
385. NCT04452318

     REGN10933 + REGN10987

     Phase 3 · completed · small_molecule

     Healthy Participants

     CT.gov ↗
386. NCT04456673

     Dupilumab SAR231893

     Phase 3 · completed · small_molecule

     Chronic Obstructive Pulmonary Disease

     CT.gov ↗
387. NCT04465487

     REGN6569

     Phase 1 · terminated · small_molecule

     Squamous Cell Carcinoma of Head and Neck

     CT.gov ↗
388. NCT04491838

     Pozelimab

     Phase 1 · completed · small_molecule

     Healthy Volunteer

     CT.gov ↗
389. NCT04502862

     SAR231893

     Approved · completed · small_molecule

     Asthma

     CT.gov ↗
390. NCT04502966

     Dupixent®

     Phase 2 · completed · mab

     Allergic Rhinoconjunctivitis

     CT.gov ↗
391. NCT04506645

     REGN5381

     Phase 1 · completed · small_molecule

     Healthy

     CT.gov ↗
392. NCT04519437

     REGN10933+REGN10987

     Phase 1 · completed · small_molecule

     Healthy

     CT.gov ↗
393. NCT04520308

     Dupilumab Only Product

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
394. NCT04526899

     BNT111

     Phase 2 · completed · mab

     Melanoma Stage III

     CT.gov ↗
395. NCT04543071

     Motixafortide

     Phase 2 · active · small_molecule

     Pancreatic Cancer

     CT.gov ↗
396. NCT04577820

     garetosmab

     Phase 3 · terminated · small_molecule

     Fibrodyplasia Ossificans Progressiva (FOP)

     CT.gov ↗
397. NCT04588948

     Intravitreal Aflibercept

     Approved · terminated · small_molecule

     Diabetic Macular Edema

     CT.gov ↗
398. NCT04590326

     REGN5668

     Phase 2 · active · small_molecule

     Ovarian Cancer

     CT.gov ↗
399. NCT04614571

     Gluten Powder

     Unknown · completed · other

     Celiac Disease

     CT.gov ↗
400. NCT04616079

     REGN6490

     Phase 1 · terminated · small_molecule

     Healthy Volunteer

     CT.gov ↗
401. NCT04616105

     REGN6490

     Phase 1 · terminated · small_molecule

     Healthy Volunteer

     CT.gov ↗
402. NCT04626635

     REGN7075

     Phase 2 · active · small_molecule

     Advanced Solid Tumors

     CT.gov ↗
403. NCT04633278

     CMP-001

     Phase 2 · terminated · small_molecule

     Squamous Cell Carcinoma of Head and Neck

     CT.gov ↗
404. NCT04646005

     Cemiplimab

     Phase 2 · completed · small_molecule

     Cervical Cancer

     CT.gov ↗
405. NCT04666441

     REGN10933+REGN10987 combination therapy

     Phase 2 · completed · small_molecule

     COVID-19

     CT.gov ↗
406. NCT04678856

     Dupilumab SAR231893

     Phase 3 · completed · small_molecule

     Chronic Rhinosinusitis Without Nasal Polyps

     CT.gov ↗
407. NCT04678882

     Placebo

     Phase 1 · completed · small_molecule

     Atopic Dermatitis

     CT.gov ↗
408. NCT04681729

     Dupilumab SAR231893

     Phase 3 · completed · small_molecule

     Cold Urticaria

     CT.gov ↗
409. NCT04684524

     Dupilumab SAR231893

     Phase 3 · completed · small_molecule

     Allergic Fungal Rhinosinusitis

     CT.gov ↗
410. NCT04695977

     CMP-001

     Phase 3 · completed · small_molecule

     Melanoma

     CT.gov ↗
411. NCT04698187

     CMP-001

     Phase 3 · completed · small_molecule

     Melanoma

     CT.gov ↗
412. NCT04701983

     Itepekimab SAR440340

     Phase 3 · active · small_molecule

     Chronic Obstructive Pulmonary Disease

     CT.gov ↗
413. NCT04706715

     Cemiplimab

     Phase 2 · active · small_molecule

     Metastatic Solid Tumor

     CT.gov ↗
414. NCT04708145

     Aflibercept Injection

     Approved · completed · small_molecule

     Diabetic Retinopathy

     CT.gov ↗
415. NCT04709575

     REGN5713

     Phase 3 · completed · small_molecule

     Allergic Rhinitis

     CT.gov ↗
416. NCT04718870

     Dupilumab SAR231893

     Approved · completed · small_molecule

     Dermatitis Atopic

     CT.gov ↗
417. NCT04722523

     Cisplatin

     Phase 1 · active · small_molecule

     Head and Neck Cancer

     CT.gov ↗
418. NCT04751487

     Itepekimab SAR440340

     Phase 3 · active · small_molecule

     Chronic Obstructive Pulmonary Disease

     CT.gov ↗
419. NCT04811716

     Pozelimab

     Phase 3 · active · small_molecule

     Paroxysmal Nocturnal Hemoglobinuria

     CT.gov ↗
420. NCT04823130

     Dupilumab SAR231893

     Approved · completed · small_molecule

     Dermatitis Atopic

     CT.gov ↗
421. NCT04826393

     ASP8374

     Phase 1 · completed · small_molecule

     Glioblastoma

     CT.gov ↗
422. NCT04831450

     Cemiplimab-Rwlc

     Phase 2 · terminated · small_molecule

     Head and Neck Squamous Cell Carcinoma

     CT.gov ↗
423. NCT04852978

     casirivimab+imdevimab

     Phase 2 · completed · small_molecule

     Healthy

     CT.gov ↗
424. NCT04863014

     evinacumab

     Phase 2 · terminated · small_molecule

     Hypertriglyceridemia

     CT.gov ↗
425. NCT04888507

     Pozelimab

     Phase 3 · active · small_molecule

     Paroxysmal Nocturnal Hemoglobinuria

     CT.gov ↗
426. NCT04916002

     vidutolimod

     Phase 2 · terminated · small_molecule

     Merkel Cell Carcinoma

     CT.gov ↗
427. NCT04940364

     Pozelimab

     Phase 1 · completed · small_molecule

     Healthy

     CT.gov ↗
428. NCT04975152

     Cemiplimab-Rwlc

     Phase 1 · active · small_molecule

     Merkel Cell Carcinoma

     CT.gov ↗
429. NCT04981717

     REGN1908-1909

     Phase 3 · terminated · small_molecule

     Allergic Rhinitis Due to Cat Allergy

     CT.gov ↗
430. NCT04982224

     REGN5093-M114

     Phase 1 · terminated · small_molecule

     Advanced NSCLC

     CT.gov ↗
431. NCT04988022

     Dupilumab

     Approved · completed · small_molecule

     Keloid

     CT.gov ↗
432. NCT04988074

     Cemiplimab

     Phase 2 · active · small_molecule

     HPV-Related Squamous Cell Carcinoma

     CT.gov ↗
433. NCT04989946

     Degarelix

     Phase 2 · active · small_molecule

     Prostate Cancer

     CT.gov ↗
434. NCT04992273

     casirivimab+imdevimab

     Phase 2 · terminated · small_molecule

     COVID-19

     CT.gov ↗
435. NCT04998604

     Dupilumab

     Approved · completed · small_molecule

     Chronic Rhinosinusitis With Nasal Polyps

     CT.gov ↗
436. NCT05031455

     Aspirin Challenge

     Phase 2 · completed · small_molecule

     Aspirin-exacerbated Respiratory Disease

     CT.gov ↗
437. NCT05036733

     Dupilumab

     Approved · active · small_molecule

     Asthma

     CT.gov ↗
438. NCT05042258

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
439. NCT05049122

     Dupilumab SAR231893

     Approved · completed · small_molecule

     Chronic Rhinosinusitis With Nasal Polyps

     CT.gov ↗
440. NCT05064085

     Cemiplimab

     Phase 1 · completed · small_molecule

     Hormone Receptor-positive Breast Cancer

     CT.gov ↗
441. NCT05070858

     Pozelimab + Cemdisiran

     Phase 3 · active · small_molecule

     Generalized Myasthenia Gravis

     CT.gov ↗
442. NCT05074433

     casirivimab+imdevimab

     Phase 3 · terminated · small_molecule

     Immunocompromised

     CT.gov ↗
443. NCT05081388

     REGN14256

     Phase 2 · terminated · small_molecule

     SARS-CoV-2

     CT.gov ↗
444. NCT05088460

     REGN4461

     Phase 2 · terminated · small_molecule

     Familial Partial Lipodystrophy

     CT.gov ↗
445. NCT05092347

     Vonsetamig

     Phase 2 · active · small_molecule

     Chronic Kidney Disease (CKD)

     CT.gov ↗
446. NCT05092581

     casirivimab+imdevimab

     Phase 2 · terminated · small_molecule

     COVID-19

     CT.gov ↗
447. NCT05094570

     Dupilumab Prefilled Syringe

     Approved · active · small_molecule

     Nasal Polyps

     CT.gov ↗
448. NCT05097287

     Dupilumab

     Approved · active · small_molecule

     Asthma

     CT.gov ↗
449. NCT05102136

     REGN9933

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
450. NCT05105152

     SC-DARIC33

     Phase 1 · active · mab

     Acute Myeloid Leukemia

     CT.gov ↗
451. NCT05125016

     REGN4336

     Phase 2 · active · small_molecule

     Metastatic Castration-resistant Prostate Cancer

     CT.gov ↗
452. NCT05128383

     Dupilumab

     Approved · completed · small_molecule

     Keloid

     CT.gov ↗
453. NCT05131204

     Cemdisiran

     Phase 3 · terminated · small_molecule

     Paroxysmal Nocturnal Hemoglobinuria

     CT.gov ↗
454. NCT05133531

     Ravulizumab

     Phase 3 · active · small_molecule

     Paroxysmal Nocturnal Hemoglobinuria

     CT.gov ↗
455. NCT05137054

     Linvoseltamab

     Phase 3 · active · small_molecule

     Multiple Myeloma

     CT.gov ↗
456. NCT05157997

     Casirivimab and Imdevimab Antibody Cocktail

     Phase 1 · terminated · small_molecule

     COVID-19

     CT.gov ↗
457. NCT05169489

     bbT369

     Phase 1 · terminated · mab

     Diffuse Large B Cell Lymphoma (DLBCL)

     CT.gov ↗
458. NCT05181683

     casirivimab+imdevimab

     Phase 2 · completed · small_molecule

     Healthy

     CT.gov ↗
459. NCT05202288

     Ervebo

     Phase 2 · active · mab

     Ebola Virus Disease

     CT.gov ↗
460. NCT05247866

     Dupilumab

     Approved · active · small_molecule

     Eosinophilic Esophagitis

     CT.gov ↗
461. NCT05259709

     89Zr˗DFO˗REGN5054

     Phase 1 · active · small_molecule

     Advanced Solid Tumor

     CT.gov ↗
462. NCT05265234

     Dupilumab

     Approved · active · small_molecule

     Eczema

     CT.gov ↗
463. NCT05268107

     Dupilumab

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
464. NCT05285839

     Dupixent

     Approved · active · small_molecule

     Atopic Dermatitis

     CT.gov ↗
465. NCT05291546

     REGN9035

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
466. NCT05293678

     REGN15160 (IV)

     Phase 1 · completed · small_molecule

     Healthy

     CT.gov ↗
467. NCT05326412

     Itepekimab SAR440340

     Phase 3 · active · small_molecule

     Chronic Obstructive Pulmonary Disease

     CT.gov ↗
468. NCT05347771

     Dupilumab

     Approved · active · small_molecule

     Asthma

     CT.gov ↗
469. NCT05352672

     Fianlimab

     Phase 3 · active · small_molecule

     Melanoma

     CT.gov ↗
470. NCT05353166

     REGN5381

     Phase 2 · terminated · small_molecule

     Heart Failure

     CT.gov ↗
471. NCT05376553

     Cemiplimab

     Phase 1 · active · small_molecule

     Locally Advanced Head and Neck Squamous Cell Carcinoma

     CT.gov ↗
472. NCT05394116

     Garetosmab

     Phase 3 · active · small_molecule

     Fibrodysplasia Ossificans Progressiva

     CT.gov ↗
473. NCT05430919

     REGN5713

     Phase 3 · completed · small_molecule

     Allergic Rhinitis

     CT.gov ↗
474. NCT05469347

     Alirocumab

     Phase 1 · completed · small_molecule

     Sepsis

     CT.gov ↗
475. NCT05481333

     REGN7999

     Phase 1 · completed · small_molecule

     Healthy

     CT.gov ↗
476. NCT05505448

     REGN14284

     Phase 1 · completed · small_molecule

     Healthy

     CT.gov ↗
477. NCT05519475

     ALN-HSD

     Phase 2 · active · small_molecule

     Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

     CT.gov ↗
478. NCT05546957

     Aspirin

     Unknown · completed · small_molecule

     Healthy Volunteer

     CT.gov ↗
479. NCT05551793

     Dupilumab

     Phase 2 · active · small_molecule

     Alopecia Areata

     CT.gov ↗
480. NCT05553834

     Alirocumab and Cemiplimab

     Phase 2 · active · other

     Non-small Cell Lung Cancer (NSCLC)

     CT.gov ↗
481. NCT05557591

     BNT116

     Phase 2 · active · small_molecule

     Advanced Non-Small Cell Lung Cancer

     CT.gov ↗
482. NCT05590585

     Dupilumab

     Approved · completed · small_molecule

     Moderate-to-Severe Atopic Dermatitis

     CT.gov ↗
483. NCT05603195

     REGN7508 (IV)

     Phase 1 · completed · small_molecule

     Healthy Volunteer

     CT.gov ↗
484. NCT05608291

     Fianlimab

     Phase 3 · active · small_molecule

     Melanoma

     CT.gov ↗
485. NCT05618808

     REGN9933

     Phase 2 · completed · small_molecule

     Venous Thromboembolism

     CT.gov ↗
486. NCT05648214

     ALN-PNP

     Phase 2 · active · small_molecule

     Healthy Volunteers

     CT.gov ↗
487. NCT05685173

     Odronextamab

     Phase 1 · active · small_molecule

     B-cell Non-Hodgkins Lymphoma (B-NHL)

     CT.gov ↗
488. NCT05704634

     Cemiplimab

     Phase 1 · active · small_molecule

     Lung Cancer

     CT.gov ↗
489. NCT05720325

     Dupilumab

     Phase 2 · active · small_molecule

     Asthma, Allergic

     CT.gov ↗
490. NCT05729139

     Cemiplimab-Rwlc

     Phase 2 · terminated · small_molecule

     Cutaneous Squamous Cell Carcinoma

     CT.gov ↗
491. NCT05730036

     Linvoseltamab

     Phase 3 · active · small_molecule

     Relapsed Refractory Multiple Myeloma (RRMM)

     CT.gov ↗
492. NCT05731128

     Dupilumab

     Phase 2 · active · small_molecule

     Colitis Ulcerative

     CT.gov ↗
493. NCT05744921

     Pozelimab

     Phase 3 · active · small_molecule

     Paroxysmal Nocturnal Hemoglobinuria

     CT.gov ↗
494. NCT05785767

     fianlimab

     Phase 3 · active · small_molecule

     Advanced Non-Small Cell Lung Cancer

     CT.gov ↗
495. NCT05788536

     DB-OTO

     Phase 2 · active · gene_therapy

     Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

     CT.gov ↗
496. NCT05800015

     fianlimab

     Phase 3 · active · small_molecule

     Non-small Cell Lung Cancer

     CT.gov ↗
497. NCT05828511

     Linvoseltamab

     Phase 3 · active · small_molecule

     Multiple Myeloma

     CT.gov ↗
498. NCT05831176

     Dupilumab

     Phase 2 · active · small_molecule

     Eosinophilic Gastritis (EoG)

     CT.gov ↗
499. NCT05850520

     22153

     Phase 3 · completed · small_molecule

     Macular Edema Secondary to Retinal Vein Occlusion

     CT.gov ↗
500. NCT05864144

     SNS-101 (anti-VISTA)

     Phase 2 · active · small_molecule

     Solid Tumor, Adult

     CT.gov ↗
501. NCT05878288

     Cemiplimab

     Phase 3 · active · small_molecule

     Cutaneous Squamous Cell Carcinoma

     CT.gov ↗
502. NCT05923424

     REGN17092

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
503. NCT05929664

     Cemiplimab

     Phase 2 · active · mab

     Locally Advanced Basal Cell Carcinoma

     CT.gov ↗
504. NCT05955508

     Linvoseltamab

     Phase 2 · active · small_molecule

     Smoldering Multiple Myeloma (SMM)

     CT.gov ↗
505. NCT05961709

     Cemiplimab

     Phase 2 · active · small_molecule

     Colon Cancer

     CT.gov ↗
506. NCT05970718

     REGN7544

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
507. NCT05976360

     Dupilumab (SAR231893)

     Phase 1 · completed · small_molecule

     Healthy Volunteer

     CT.gov ↗
508. NCT05976373

     Dupilumab (SAR231893)

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
509. NCT05976386

     Dupilumab (SAR231893)

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
510. NCT05983068

     Dupilumab

     Approved · active · small_molecule

     Dermatitis, Atopic

     CT.gov ↗
511. NCT05989126

     aflibercept 8 mg PFS

     Phase 3 · completed · small_molecule

     Diabetic Macular Edema (DME)

     CT.gov ↗
512. NCT06012448

     Dupilumab

     Approved · completed · small_molecule

     Dermal Hypersensitivity Reaction

     CT.gov ↗
513. NCT06024408

     ALN-PNP

     Phase 1 · completed · small_molecule

     Nonalcoholic Fatty Liver Disease (NAFLD)

     CT.gov ↗
514. NCT06091254

     Odronextamab

     Phase 3 · active · small_molecule

     Follicular Lymphoma (FL)

     CT.gov ↗
515. NCT06091865

     Odronextamab

     Phase 3 · active · small_molecule

     Diffuse Large B-cell Lymphoma (DLBCL)

     CT.gov ↗
516. NCT06097364

     Odronextamab

     Phase 3 · active · small_molecule

     Follicular Lymphoma (FL)

     CT.gov ↗
517. NCT06101095

     Dupilumab

     Approved · active · small_molecule

     Eosinophilic Oesophagitis

     CT.gov ↗
518. NCT06114238

     Itepekimab AI

     Phase 1 · completed · small_molecule

     Chronic Obstructive Pulmonary Disease

     CT.gov ↗
519. NCT06121180

     ZIV-Aflibercept

     Phase 2 · active · small_molecule

     Metastatic Uveal Melanoma

     CT.gov ↗
520. NCT06122922

     Hyperpolarized Xe129

     Phase 2 · terminated · small_molecule

     Pulmonary Artery Hypertension

     CT.gov ↗
521. NCT06128629

     NTLA-2001

     Phase 3 · active · mab

     Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

     CT.gov ↗
522. NCT06137482

     REGN13335

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
523. NCT06140524

     Linvoseltamab

     Phase 2 · active · small_molecule

     Monoclonal Gammopathy of Undetermined Significance (MGUS)

     CT.gov ↗
524. NCT06149286

     Odronextamab

     Phase 3 · active · small_molecule

     Relapsed/Refractory Follicular Lymphoma

     CT.gov ↗
525. NCT06161441

     Fianlimab

     Phase 2 · active · small_molecule

     Resectable Non-small Cell Lung Cancer

     CT.gov ↗
526. NCT06162572

     S095018

     Phase 2 · active · small_molecule

     Non-small Cell Lung Cancer (NSCLC)

     CT.gov ↗
527. NCT06190951

     cemiplimab

     Phase 2 · active · small_molecule

     Melanoma

     CT.gov ↗
528. NCT06191315

     Dupilumab

     Phase 3 · active · small_molecule

     Wheezing

     CT.gov ↗
529. NCT06205836

     Cemiplimab

     Phase 2 · active · small_molecule

     Colorectal Cancer

     CT.gov ↗
530. NCT06208306

     Itepekimab SAR440340

     Phase 3 · active · small_molecule

     Chronic Obstructive Pulmonary Disease

     CT.gov ↗
531. NCT06226610

     Dupilumab

     Phase 2 · active · small_molecule

     Pruritis

     CT.gov ↗
532. NCT06230224

     Odronextamab

     Phase 2 · active · small_molecule

     B-cell Non-Hodgkin Lymphoma (B-NHL)

     CT.gov ↗
533. NCT06237309

     REGN5381

     Phase 2 · terminated · small_molecule

     Heart Failure

     CT.gov ↗
534. NCT06246916

     Fianlimab

     Phase 3 · active · small_molecule

     Melanoma

     CT.gov ↗
535. NCT06280391

     Itepekimab (SAR440340)

     Phase 2 · completed · small_molecule

     Bronchiectasis

     CT.gov ↗
536. NCT06292780

     Linvoseltamab

     Phase 2 · active · small_molecule

     Relapsed/Refractory Systemic Light Chain Amyloidosis

     CT.gov ↗
537. NCT06293053

     Dupilumab

     Phase 3 · active · small_molecule

     Prurigo Nodularis

     CT.gov ↗
538. NCT06299098

     Trevogrumab-Part A

     Phase 2 · active · small_molecule

     Obesity

     CT.gov ↗
539. NCT06299111

     REGN9933

     Phase 2 · completed · small_molecule

     Venous Thromboembolism

     CT.gov ↗
540. NCT06351592

     ALN-SOD

     Phase 2 · active · small_molecule

     Amyotrophic Lateral Sclerosis (ALS)

     CT.gov ↗
541. NCT06352073

     Dupilumab

     Approved · active · small_molecule

     Eosinophilic Esophagitis

     CT.gov ↗
542. NCT06369467

     linvoseltamab

     Phase 1 · active · small_molecule

     Food Allergy

     CT.gov ↗
543. NCT06373146

     Tirzepatide

     Phase 2 · completed · small_molecule

     Obesity

     CT.gov ↗
544. NCT06376526

     Linvoseltamab

     Phase 3 · active · small_molecule

     Multiple Myeloma

     CT.gov ↗
545. NCT06379789

     REGV131

     Phase 2 · active · small_molecule

     Hemophilia B

     CT.gov ↗
546. NCT06384820

     Cemiplimab

     Phase 3 · active · small_molecule

     Cutaneous Squamous Cell Carcinoma

     CT.gov ↗
547. NCT06385262

     Alirocumab

     Phase 2 · on hold · small_molecule

     Non Small Cell Lung Cancer

     CT.gov ↗
548. NCT06413680

     REGN10597

     Phase 2 · active · small_molecule

     Melanoma

     CT.gov ↗
549. NCT06421636

     REGN7999

     Phase 2 · active · small_molecule

     Non-Transfusion Dependent Beta-Thalassemia (NTDT)

     CT.gov ↗
550. NCT06422507

     8 mg aflibercept (BAY 86-5321) (High Dose)

     Phase 3 · completed · small_molecule

     Diabetic Macular Edema

     CT.gov ↗
551. NCT06444178

     Aspirin

     Phase 1 · completed · small_molecule

     Healthy Volunteers

     CT.gov ↗
552. NCT06444880

     Ubamatamab

     Phase 2 · active · small_molecule

     SMARCB1-Deficient Malignancies

     CT.gov ↗
553. NCT06448026

     Cemiplimab

     Phase 2 · active · small_molecule

     Locally Recurrent Oral Cavity Squamous Cell Carcinoma

     CT.gov ↗
554. NCT06449313

     Cemiplimab-Rwlc

     Phase 2 · active · small_molecule

     Non-small Cell Lung Cancer Stage III

     CT.gov ↗
555. NCT06452771

     ALN-ANG3

     Phase 1 · active · small_molecule

     Healthy Volunteers With Hyperlipidemia

     CT.gov ↗
556. NCT06454630

     REGN7508

     Phase 2 · completed · small_molecule

     Venous Thromboembolism

     CT.gov ↗
557. NCT06465329

     cemiplimab

     Phase 3 · active · small_molecule

     Non-small Cell Lung Cancer

     CT.gov ↗
558. NCT06469281

     Cemiplimab

     Phase 1 · active · small_molecule

     Epithelial Ovarian Cancer

     CT.gov ↗
559. NCT06479863

     Pozelimab/Cemdisiran

     Phase 1 · active · other

     Sporadic Inclusion Body Myositis (sIBM)

     CT.gov ↗
560. NCT06491914

     Aflibercept 8 mg

     Phase 3 · active · small_molecule

     Neovascular Age-Related Macular Degeneration

     CT.gov ↗
561. NCT06541704

     Pozelimab

     Phase 3 · active · small_molecule

     Age-related Macular Degeneration (AMD)

     CT.gov ↗
562. NCT06548100

     Mibavademab

     Phase 3 · active · small_molecule

     Generalized Lipodystrophy

     CT.gov ↗
563. NCT06571708

     Gemcitabine

     Phase 2 · active · small_molecule

     Bladder Cancer

     CT.gov ↗
564. NCT06572228

     Dupilumab

     Approved · active · small_molecule

     Asthma

     CT.gov ↗
565. NCT06585410

     Cemiplimab

     Phase 3 · active · small_molecule

     Cutaneous Squamous Cell Carcinoma (CSCC)

     CT.gov ↗
566. NCT06591598

     Aflibercept (BAY86-5321, Eylea)

     Approved · completed · small_molecule

     Diabetic Macular Edema

     CT.gov ↗
567. NCT06593600

     REGN7544

     Phase 2 · active · small_molecule

     Postural Orthostatic Tachycardia Syndrome (POTS)

     CT.gov ↗
568. NCT06594991

     Fianlimab

     Phase 2 · active · small_molecule

     Advanced Melanoma

     CT.gov ↗
569. NCT06602726

     REGN1908

     Phase 3 · completed · small_molecule

     Allergic Conjunctivitis

     CT.gov ↗
570. NCT06602739

     REGN5713

     Phase 3 · active · small_molecule

     Allergic Conjunctivitis

     CT.gov ↗
571. NCT06608901

     REGN7544

     Phase 2 · completed · small_molecule

     Sepsis-Induced Hypotension

     CT.gov ↗
572. NCT06616584

     Cemiplimab

     Phase 3 · active · mab

     Recurrent Lung Non-Small Cell Carcinoma

     CT.gov ↗
573. NCT06623656

     Cemiplimab

     Phase 2 · active · small_molecule

     Carcinoma, Non-Small-Cell Lung

     CT.gov ↗
574. NCT06651593

     SAR444881

     Phase 2 · active · small_molecule

     Solid Tumors

     CT.gov ↗
575. NCT06662994

     Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)

     Approved · active · small_molecule

     Diabetic Macular Edema (DME)

     CT.gov ↗
576. NCT06665828

     REGN9533

     Phase 1 · completed · small_molecule

     Healthy Volunteer

     CT.gov ↗
577. NCT06665971

     Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

     Approved · active · small_molecule

     Eosinophilic Esophagitis (EoE)

     CT.gov ↗
578. NCT06669234

     ALN-F1202

     Phase 1 · active · small_molecule

     Healthy Volunteer

     CT.gov ↗
579. NCT06669247

     Linvoseltamab

     Phase 2 · active · small_molecule

     Relapsed/Refractory Multiple Myeloma

     CT.gov ↗
580. NCT06672237

     nexiguran ziclumeran

     Phase 3 · active · mab

     Neuromuscular Disease

     CT.gov ↗
581. NCT06687967

     Dupilumab

     Phase 3 · active · small_molecule

     Lichen Simplex Chronicus

     CT.gov ↗
582. NCT06687980

     Dupilumab

     Phase 3 · active · small_molecule

     Lichen Simplex Chronicus

     CT.gov ↗
583. NCT06691113

     Itepekimab (SAR440340)

     Phase 2 · active · small_molecule

     Chronic Rhinosinusitis Without Nasal Polyps

     CT.gov ↗
584. NCT06769698

     FDC fianlimab+cemiplimab

     Phase 2 · active · small_molecule

     Head and Neck Squamous Cell Carcinoma (HNSCC)

     CT.gov ↗
585. NCT06784349

     ALN-APOC3

     Phase 1 · completed · small_molecule

     Dyslipidemia

     CT.gov ↗
586. NCT06784726

     Odronextamab

     Phase 2 · active · mab

     Recurrent Diffuse Large B-Cell Lymphoma

     CT.gov ↗
587. NCT06787612

     Ubamatamab

     Phase 2 · active · small_molecule

     Ovarian Cancer

     CT.gov ↗
588. NCT06790602

     Cemiplimab Plus Gemcitabine

     Phase 2 · active · small_molecule

     Pancreatic Ductal Adenocarcinoma (mPDAC)

     CT.gov ↗
589. NCT06826768

     REGN5678

     Phase 1 · active · small_molecule

     Prostate Cancer

     CT.gov ↗
590. NCT06833190

     REGN5381

     Phase 2 · terminated · small_molecule

     Uncontrolled Hypertension

     CT.gov ↗
591. NCT06834347

     Itepekimab (SAR440340)

     Phase 3 · active · small_molecule

     Chronic Rhinosinusitis With Nasal Polyps

     CT.gov ↗
592. NCT06834360

     Itepekimab (SAR440340)

     Phase 3 · active · small_molecule

     Chronic Rhinosinusitis With Nasal Polyps

     CT.gov ↗
593. NCT06836609

     ALN-CIDEB

     Phase 2 · active · small_molecule

     Metabolic Dysfunction-Associated Steatotic Liver Disease

     CT.gov ↗
594. NCT06848088

     Fianlimab+cemiplimab

     Phase 2 · active · small_molecule

     Melanoma

     CT.gov ↗
595. NCT06855212

     Cemiplimab

     Phase 2 · active · small_molecule

     Head and Neck Squamous Cell Carcinoma

     CT.gov ↗
596. NCT06865339

     Cemiplimab

     Phase 2 · active · small_molecule

     NSCLC

     CT.gov ↗
597. NCT06887088

     Encorafenib + Binimetinib

     Phase 2 · active · small_molecule

     Melanoma BRAF V600E/K Mutated

     CT.gov ↗
598. NCT06902376

     Cemiplimab

     Phase 1 · active · mab

     Anaplastic Thyroid Cancer

     CT.gov ↗
599. NCT06910124

     Linvoseltamab

     Phase 3 · active · small_molecule

     Multiple Myeloma

     CT.gov ↗
600. NCT06931717

     cemiplimab

     Phase 3 · active · small_molecule

     Non-small Cell Lung Cancer

     CT.gov ↗
601. NCT06932562

     Linvoseltamab

     Phase 3 · active · small_molecule

     Multiple Myeloma

     CT.gov ↗
602. NCT06970405

     Garetosmab

     Phase 1 · terminated · small_molecule

     Obesity

     CT.gov ↗
603. NCT06975787

     Vonsetamig

     Phase 1 · active · small_molecule

     Lupus Nephritis (LN)

     CT.gov ↗
604. NCT06981325

     Cemiplimab

     Phase 2 · active · small_molecule

     Basal Cell Carcinoma (BCC)

     CT.gov ↗
605. NCT07001618

     MaaT033 capsule

     Phase 2 · active · small_molecule

     NSCLC (Advanced Non-small Cell Lung Cancer)

     CT.gov ↗
606. NCT07015905

     REGN7508

     Phase 3 · active · small_molecule

     Venous Thromboembolism (VTE)

     CT.gov ↗
607. NCT07053423

     Dupilumab

     Approved · active · small_molecule

     Chronic Obstructive Pulmonary Disease

     CT.gov ↗
608. NCT07058012

     Cemiplimab

     Phase 2 · active · small_molecule

     Colo-rectal Cancer

     CT.gov ↗
609. NCT07112378

     Dupilumab

     Phase 3 · active · small_molecule

     Eosinophilic Esophagitis (EoE)

     CT.gov ↗
610. NCT07128641

     Odronextamab

     Phase 2 · active · mab

     Follicular Lymphoma

     CT.gov ↗
611. NCT07142343

     Pozelimab

     Approved · active · small_molecule

     CHAPLE Disease

     CT.gov ↗
612. NCT07154290

     Ubamatamab

     Phase 2 · active · small_molecule

     Advanced/Metastatic Non-Small Cell Lung Cancer

     CT.gov ↗
613. NCT07154745

     Pozelimab

     Phase 3 · active · small_molecule

     Paroxysmal Nocturnal Hemoglobinuria

     CT.gov ↗
614. NCT07175428

     REGN7508

     Phase 3 · active · small_molecule

     Atrial Fibrillation (AF)

     CT.gov ↗
615. NCT07181941

     Linvoseltamab

     Phase 2 · active · mab

     Recurrent Multiple Myeloma

     CT.gov ↗
616. NCT07187089

     dupilumab

     Approved · terminated · small_molecule

     Severe Atopic Dermatitis (AD)

     CT.gov ↗
617. NCT07187401

     ALN-CFB

     Phase 2 · active · small_molecule

     Paroxysmal Nocturnal Hemoglobinuria (PNH)

     CT.gov ↗
618. NCT07188896

     Fianlimab

     Phase 2 · active · small_molecule

     Advanced Renal Cell Carcinoma (aRCC)

     CT.gov ↗
619. NCT07213778

     REGN7508

     Phase 3 · active · small_molecule

     Symptomatic Venous Thromboembolism (VTE)

     CT.gov ↗
620. NCT07216066

     ALN-SNCA

     Phase 1 · active · small_molecule

     Parkinsons Disease

     CT.gov ↗
621. NCT07218770

     REGN7041

     Phase 2 · active · small_molecule

     Active Noninfectious Uveitis Affecting the Posterior Segment

     CT.gov ↗
622. NCT07220772

     Mibavademab

     Phase 3 · active · small_molecule

     Monogenic Obesity

     CT.gov ↗
623. NCT07220785

     Mibavademab

     Phase 3 · active · small_molecule

     Generalized Lipodystrophy

     CT.gov ↗
624. NCT07222761

     Linvoseltamab

     Phase 3 · active · small_molecule

     Relapsed and/or Refractory Multiple Myeloma (RRMM)

     CT.gov ↗
625. NCT07223541

     Cemiplimab 350 MG Intravenous Solution

     Phase 2 · active · small_molecule

     Clear Cell Renal Cell Carcinoma

     CT.gov ↗
626. NCT07224022

     Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]

     Phase 2 · active · small_molecule

     Colon Cancer

     CT.gov ↗
627. NCT07230834

     Pozelimab

     Phase 1 · active · small_molecule

     Geographic Atrophy (GA)

     CT.gov ↗
628. NCT07234058

     Cemiplimab

     Phase 2 · active · small_molecule

     Pleural Mesotheliomas

     CT.gov ↗
629. NCT07235917

     Mibavademab

     Phase 2 · active · small_molecule

     Functional Hypothalamic Amenorrhea (FHA)

     CT.gov ↗
630. NCT07251413

     cemiplimab

     Phase 2 · active · small_molecule

     Cutaneous Basal Cell Carcinoma

     CT.gov ↗
631. NCT07271186

     ALN-ANG3

     Phase 2 · active · small_molecule

     Diabetic Kidney Disease (DKD)

     CT.gov ↗
632. NCT07281768

     Oxaliplatin

     Phase 2 · active · small_molecule

     Colorectal Cancer

     CT.gov ↗
633. NCT07286214

     Sarilumab

     Approved · active · small_molecule

     Polymyalgia Rheumatica

     CT.gov ↗
634. NCT07309432

     REGN5713

     Phase 3 · active · small_molecule

     Allergic Conjunctivitis

     CT.gov ↗
635. NCT07309614

     Dupilumab Prefilled Syringe

     Phase 3 · active · small_molecule

     Asthma Control

     CT.gov ↗
636. NCT07318597

     REGN13335

     Phase 2 · active · small_molecule

     Pulmonary Arterial Hypertension (PAH)

     CT.gov ↗
637. NCT07318610

     REGN7508

     Phase 3 · active · small_molecule

     Peripheral Artery Disease (PAD)

     CT.gov ↗
638. NCT07365839

     Arm 1 cemiplimab

     Phase 1 · active · small_molecule

     Hepatocellular Carcinoma

     CT.gov ↗
639. NCT07387198

     Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

     Phase 2 · active · small_molecule

     Merkel Cell Carcinoma, Stage I

     CT.gov ↗
640. NCT07393282

     Linvoseltamab

     Phase 3 · active · small_molecule

     High Risk Smoldering Multiple Myeloma (HR-SMM)

     CT.gov ↗
641. NCT07410117

     REGN7508

     Phase 3 · active · small_molecule

     Cancer-Associated Thrombosis (CAT)

     CT.gov ↗
642. NCT07414992

     Cemiplimab

     Phase 2 · active · small_molecule

     Bladder Urothelial Carcinoma

     CT.gov ↗
643. NCT07424144

     Itepekimab (SAR440340)

     Phase 3 · active · small_molecule

     Chronic Rhinosinusitis With Nasal Polyps

     CT.gov ↗
644. NCT07428369

     Linvoseltamab

     Phase 3 · active · small_molecule

     Multiple Myeloma (MM)

     CT.gov ↗
645. NCT07430956

     REGN7508

     Phase 3 · active · small_molecule

     Atrial Fibrillation (AF)

     CT.gov ↗
646. NCT07431086

     Olatorepatide

     Phase 2 · active · small_molecule

     Overweight or Obesity

     CT.gov ↗
647. NCT07433673

     Cemiplimab

     Phase 2 · active · small_molecule

     Colon and Rectal Cancer

     CT.gov ↗
648. NCT07450183

     Cemiplimab

     Phase 2 · active · small_molecule

     Lung Cancer (NSCLC)

     CT.gov ↗
649. NCT07455851

     Linvoseltamab

     Phase 3 · active · small_molecule

     Relapsed Refractory Multiple Myeloma (RRMM)

     CT.gov ↗
650. NCT07477704

     Alirocumab

     Phase 3 · active · small_molecule

     Hypercholesterolemia

     CT.gov ↗
651. NCT07484230

     Itepekimab (SAR440340)

     Phase 3 · active · small_molecule

     Chronic Rhinosinusitis With Nasal Polyps

     CT.gov ↗
652. NCT07493304

     REGN7508

     Phase 3 · active · small_molecule

     Venous Thromboembolism (VTE)

     CT.gov ↗
653. NCT07526116

     REGN22044

     Phase 1 · active · small_molecule

     Healthy Volunteer

     CT.gov ↗
654. NCT07527910

     ALN-PNP

     Phase 2 · active · small_molecule

     Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

     CT.gov ↗
655. NCT07527923

     REGN20423

     Phase 1 · active · small_molecule

     Healthy Volunteer

     CT.gov ↗
656. NCT07543055

     BPX-601

     Phase 1 · active · gene_therapy

     Prostate Cancer

     CT.gov ↗
657. NCT07559513

     garetosmab

     Phase 3 · active · small_molecule

     Fibrodysplasia Ossificans Progressiva (FOP)

     CT.gov ↗
658. NCT07567469

     Cemiplimab

     Phase 2 · active · small_molecule

     High-Grade Glioma (HGG)

     CT.gov ↗
659. NCT07587658

     dupilumab

     Approved · active · small_molecule

     Chronic Obstructive Pulmonary Disease (COPD)

     CT.gov ↗
660. NCT07594093

     REGN20934

     Phase 1 · active · small_molecule

     Overweight or Obesity

     CT.gov ↗
661. NCT07594106

     REGN15505

     Phase 2 · active · small_molecule

     Metastatic Castration-Resistant Prostate Cancer (mCRPC)

     CT.gov ↗